Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study

Table 1

Baseline demographic and clinical characteristics.

	Characteristics; n (% out of 106)
Sex
Men	47 (44.34)
Women	59 (55.66)
Median age (IQR) at onset of uveitis, years	29.00 (20.50-40.00)
Associated disease
No (idiopathic uveitis)	12 (11.32)
Yes	94 (88.68)
Behçet syndrome	66 (62.26)
Other (JIA, PsA, AS, VKH, and IBD)	28 (26.42)
Median follow-up, months	36.02 (16.27-59.17)
Median duration of uveitis at ADA beginning (IQR), years	4.00 (1.00-11.00)
Type of uveitis
Anterior	45 (42.45)
Posterior and/or panuveitis (and/or intermediate)	51 (48.11)
Unilateral	42 (39.62)
Bilateral	64 (60.38)
Previous treatment
None	17 (16.04)
Only synthetic DMARDs	59 (55.66)
Only biologics	7 (6.60)
Synthetic DMARDs and biologics	23 (21.70)
Baseline treatment
None	31 (29.25)
Only synthetic DMARDs	53 (50.00)
Only biologics	7 (6.60)
Synthetic DMARDs and biologics	4 (3.77)
Missing	11 (10.38)
Ocular flare
In the 12 months before ADA treatment	76 (71.70)
At baseline	70 (66.04)

ADA: adalimumab; AS: ankylosing spondylitis; DMARDs: disease-modifying antirheumatic drugs; IBD: intestinal bowel disease; JIA: juvenile idiopathic arthritis; PsA: psoriatic arthritis; VKH: Vogt-Koyanagi-Harada.